Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Direct-acting antiviral (HCV NS5A inhibitor)

Daclatasvir

Brand names: Daklinza

Daclatasvir is a direct-acting antiviral for chronic hepatitis C, used in combination with other agents such as sofosbuvir across several genotypes.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits the hepatitis C virus NS5A protein, which is essential for viral RNA replication and assembly, suppressing viral production.

Prescribing in practice

  • When combined with sofosbuvir and amiodarone there is a risk of serious symptomatic bradycardia, so this combination should be avoided or used only with cardiac monitoring.
  • It is a substrate of CYP3A4, so strong inducers reduce its efficacy and dose adjustment may be required with certain interacting drugs.
  • Reactivation of hepatitis B can occur during hepatitis C treatment, so HBV status should be assessed beforehand.

Monitoring

Monitor virological response and assess for hepatitis B reactivation, with cardiac monitoring if amiodarone cannot be avoided.

Counselling the patient

  • Report dizziness, fainting or a very slow heartbeat, especially if you take amiodarone.
  • Take exactly as directed alongside its companion antiviral and do not miss doses.

Evidence & guidelines

Efficacy in combination regimens is supported by registration trials and NICE technology appraisal guidance for hepatitis C.

Reference: SmPC Daklinza; EASL HCV Guidelines 2020; AASLD/IDSA HCV Guidance; FDA Drug Safety Communication Mar 2015 (amiodarone + sofosbuvir); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways